These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | ||||
|
|
||||||||||
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | ||||||||||
|
|||||||||||
|
|
|
|||||||||
(Address of principal executive offices) | (Zip Code) |
Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
|
|
|
|
þ | Accelerated filer | ☐ | |||||||||||
Non-accelerated filer | ☐ | Smaller reporting company |
|
|||||||||||
Emerging growth company |
|
Page | |||||
Item 1. Financial Statements
(Unaudited).
|
|||||
July 1, 2023 | April 1, 2023 | ||||||||||
ASSETS | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ |
|
$ |
|
|||||||
Accounts receivable, net of allowance of $415 and $369 as of July 1, 2023 and April 1, 2023, respectively |
|
|
|||||||||
Inventories |
|
|
|||||||||
Prepaid expenses |
|
|
|||||||||
Other receivables |
|
|
|||||||||
Other current assets |
|
|
|||||||||
Total current assets |
|
|
|||||||||
Property and equipment, net of accumulated depreciation of $1,933,949 and $1,900,317 as of July 1, 2023 and April 1, 2023, respectively |
|
|
|||||||||
Goodwill |
|
|
|||||||||
Intangible assets, net |
|
|
|||||||||
Long-term investments |
|
|
|||||||||
Other non-current assets |
|
|
|||||||||
Total assets | $ |
|
$ |
|
|||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ |
|
$ |
|
|||||||
Accrued liabilities |
|
|
|||||||||
Other current liabilities |
|
|
|||||||||
Total current liabilities |
|
|
|||||||||
Long-term debt |
|
|
|||||||||
Other long-term liabilities |
|
|
|||||||||
Total liabilities |
|
|
|||||||||
Commitments and contingent liabilities
(Note 7)
|
|||||||||||
Stockholders’ equity: | |||||||||||
Preferred stock, $.0001 par value; 5,000 shares authorized; no shares issued and outstanding |
|
|
|||||||||
Common stock and additional paid-in capital, $.0001 par value; 405,000 shares authorized; 98,048 and 98,649 shares issued and outstanding at July 1, 2023 and April 1, 2023, respectively |
|
|
|||||||||
Accumulated other comprehensive loss |
(
|
(
|
|||||||||
Retained earnings |
|
|
|||||||||
Total stockholders’ equity |
|
|
|||||||||
Total liabilities and stockholders’ equity | $ |
|
$ |
|
Three Months Ended | |||||||||||
July 1, 2023 | July 2, 2022 | ||||||||||
Revenue | $ |
|
$ |
|
|||||||
Cost of goods sold |
|
|
|||||||||
Gross profit |
|
|
|||||||||
Operating expenses: | |||||||||||
Research and development |
|
|
|||||||||
Selling, general and administrative |
|
|
|||||||||
Other operating expense |
|
|
|||||||||
Total operating expenses |
|
|
|||||||||
Operating (loss) income |
(
|
|
|||||||||
Interest expense |
(
|
(
|
|||||||||
Other income (expense), net |
|
(
|
|||||||||
(Loss) income before income taxes |
(
|
|
|||||||||
Income tax benefit (expense) |
|
(
|
|||||||||
Net (loss) income | $ |
(
|
$ |
|
|||||||
Net (loss) income per share: | |||||||||||
Basic | $ |
(
|
$ |
|
|||||||
Diluted | $ |
(
|
$ |
|
|||||||
Weighted-average shares of common stock outstanding: | |||||||||||
Basic |
|
|
|||||||||
Diluted |
|
|
Three Months Ended | |||||||||||
July 1, 2023 | July 2, 2022 | ||||||||||
Net (loss) income | $ |
(
|
$ |
|
|||||||
Other comprehensive loss, net of tax: | |||||||||||
Foreign currency translation adjustment, including intra-entity foreign currency transactions that are of a long-term investment nature |
(
|
(
|
|||||||||
Reclassification adjustments, net of tax: | |||||||||||
Amortization of pension actuarial (gain) loss |
(
|
|
|||||||||
Other comprehensive loss |
(
|
(
|
|||||||||
Total comprehensive (loss) income | $ |
(
|
$ |
|
Common Stock and
Additional Paid-In Capital |
Accumulated Other Comprehensive (Loss) Income | Retained Earnings | |||||||||||||||||||||||||||
Three Months Ended | Shares | Amount | Total | ||||||||||||||||||||||||||
Balance, April 1, 2023 |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
||||||||||||||||||||
Net loss | — |
|
|
(
|
(
|
||||||||||||||||||||||||
Other comprehensive loss | — |
|
(
|
|
(
|
||||||||||||||||||||||||
Exercise of stock options and vesting of restricted stock units, net of shares withheld for employee taxes
|
|
(
|
|
|
(
|
||||||||||||||||||||||||
Issuance of common stock in connection with employee stock purchase plan |
|
|
|
|
|
||||||||||||||||||||||||
Repurchase of common stock, including transaction costs and excise tax |
(
|
(
|
|
(
|
(
|
||||||||||||||||||||||||
Stock-based compensation
|
— |
|
|
|
|
||||||||||||||||||||||||
Balance, July 1, 2023 |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
||||||||||||||||||||
Balance, April 2, 2022 |
|
$ |
|
$ |
|
$ |
|
$ |
|
||||||||||||||||||||
Net income
|
— |
|
|
|
|
||||||||||||||||||||||||
Other comprehensive loss | — |
|
(
|
|
(
|
||||||||||||||||||||||||
Exercise of stock options and vesting of restricted stock units, net of shares withheld for employee taxes
|
|
(
|
|
|
(
|
||||||||||||||||||||||||
Issuance of common stock in connection with employee stock purchase plan
|
|
|
|
|
|
||||||||||||||||||||||||
Repurchase of common stock, including transaction costs
|
(
|
(
|
|
(
|
(
|
||||||||||||||||||||||||
Stock-based compensation
|
— |
|
|
|
|
||||||||||||||||||||||||
Balance, July 2, 2022 |
|
$ |
|
$ |
(
|
$ |
|
$ |
|
Three Months Ended | |||||||||||
July 1, 2023 | July 2, 2022 | ||||||||||
Cash flows from operating activities: | |||||||||||
Net (loss) income | $ |
(
|
$ |
|
|||||||
Adjustments to reconcile net (loss) income to net cash provided by operating activities: | |||||||||||
Depreciation |
|
|
|||||||||
Intangible assets amortization |
|
|
|||||||||
Deferred income taxes |
(
|
(
|
|||||||||
Stock-based compensation expense |
|
|
|||||||||
Other, net |
|
|
|||||||||
Changes in operating assets and liabilities: | |||||||||||
Accounts receivable, net |
(
|
|
|||||||||
Inventories |
(
|
(
|
|||||||||
Prepaid expenses and other assets |
(
|
|
|||||||||
Accounts payable and accrued liabilities |
|
|
|||||||||
Income taxes payable and receivable |
(
|
|
|||||||||
Other liabilities |
(
|
|
|||||||||
Net cash provided by operating activities |
|
|
|||||||||
Cash flows from investing activities: | |||||||||||
Purchase of property and equipment |
(
|
(
|
|||||||||
Proceeds from sales of property and equipment |
|
|
|||||||||
Other investing activities |
(
|
|
|||||||||
Net cash used in investing activities |
(
|
(
|
|||||||||
Cash flows from financing activities: | |||||||||||
Repurchase of common stock, including transaction costs |
(
|
(
|
|||||||||
Proceeds from the issuance of common stock |
|
|
|||||||||
Tax withholding paid on behalf of employees for restricted stock units |
(
|
(
|
|||||||||
Other financing activities |
(
|
(
|
|||||||||
Net cash used in financing activities |
(
|
(
|
|||||||||
Effect of exchange rate changes on cash, cash equivalents and restricted cash |
(
|
(
|
|||||||||
Net decrease in cash, cash equivalents and restricted cash |
(
|
(
|
|||||||||
Cash, cash equivalents and restricted cash at the beginning of the period |
|
|
|||||||||
Cash, cash equivalents and restricted cash at the end of the period | $ |
|
$ |
|
|||||||
Reconciliation of cash, cash equivalents and restricted cash: | |||||||||||
Cash and cash equivalents | $ |
|
$ |
|
|||||||
Restricted cash included in "Other current assets" and "Other non-current assets" |
|
|
|||||||||
Total cash, cash equivalents and restricted cash | $ |
|
$ |
|
|||||||
Supplemental disclosure of cash flow information: | |||||||||||
Capital expenditures included in liabilities | $ |
|
$ |
|
July 1, 2023 | April 1, 2023 | ||||||||||
Raw materials | $ |
|
$ |
|
|||||||
Work in process |
|
|
|||||||||
Finished goods |
|
|
|||||||||
Total inventories | $ |
|
$ |
|
HPA
|
CSG
|
ACG
|
Total | ||||||||||||||||||||
Balance as of April 1, 2023
(1)
|
$ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Effect of changes in foreign currency exchange rates |
|
|
|
|
|||||||||||||||||||
Balance as of July 1, 2023
(1)
|
$ |
|
$ |
|
$ |
|
$ |
|
July 1, 2023 | April 1, 2023 | ||||||||||||||||||||||
Gross
Carrying Amount |
Accumulated
Amortization |
Gross
Carrying Amount |
Accumulated
Amortization |
||||||||||||||||||||
Developed technology | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Customer relationships |
|
|
|
|
|||||||||||||||||||
Technology licenses |
|
|
|
|
|||||||||||||||||||
Trade names |
|
|
|
|
|||||||||||||||||||
In-process research and development |
|
N/A |
|
N/A | |||||||||||||||||||
Total
(1)
|
$ |
|
$ |
|
$ |
|
$ |
|
Total |
Quoted Prices In
Active Markets For Identical Assets (Level 1) |
Significant Other
Observable Inputs (Level 2) |
Significant
Unobservable Inputs (Level 3) |
||||||||||||||||||||
July 1, 2023 | |||||||||||||||||||||||
Marketable equity securities | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Invested funds in deferred compensation plan
(1)
|
|
|
|
|
|||||||||||||||||||
April 1, 2023 | |||||||||||||||||||||||
Marketable equity securities | $ |
|
$ |
|
$ |
|
$ |
|
|||||||||||||||
Invested funds in deferred compensation plan
(1)
|
|
|
|
|
|||||||||||||||||||
Contingent earn-out liability
(2)
|
(
|
|
|
(
|
July 1, 2023 | April 1, 2023 | ||||||||||
1.750% senior notes due 2024 | $ |
|
$ |
|
|||||||
4.375% senior notes due 2029 |
|
|
|||||||||
3.375% senior notes due 2031 |
|
|
|||||||||
Finance leases and other |
|
|
|||||||||
Unamortized premium, discount and issuance costs, net |
(
|
(
|
|||||||||
Less current portion of long-term debt |
(
|
(
|
|||||||||
Total long-term debt | $ |
|
$ |
|
Three Months Ended | |||||||||||
July 1, 2023 | July 2, 2022 | ||||||||||
United States | $ |
|
$ |
|
|||||||
China |
|
|
|||||||||
Other Asia |
|
|
|||||||||
Taiwan |
|
|
|||||||||
Europe |
|
|
|||||||||
Total revenue
|
$ |
|
$ |
|
Three Months Ended July 1, 2023 | |||||||||||||||||
Cost of Goods Sold | Other Operating Expense | Total | |||||||||||||||
Contract termination and other costs | $ |
|
$ |
|
$ |
|
|||||||||||
Asset impairment costs |
|
|
|
||||||||||||||
One-time employee termination benefits |
|
|
|
||||||||||||||
Total
|
$ |
|
$ |
|
$ |
|
One-Time Employee Termination Benefits | Contract Termination and Other Costs | Total | |||||||||||||||
Accrued restructuring balance as of April 1, 2023 | $ |
|
$ |
|
$ |
|
|||||||||||
Costs incurred and charged to expense |
|
|
|
||||||||||||||
Cash payments |
(
|
(
|
(
|
||||||||||||||
Accrued restructuring balance as of July 1, 2023 | $ |
|
$ |
|
$ |
|
Three Months Ended | |||||||||||
July 1, 2023 | July 2, 2022 | ||||||||||
Revenue: | |||||||||||
HPA | $ |
|
$ |
|
|||||||
CSG |
|
|
|||||||||
ACG |
|
|
|||||||||
Total revenue | $ |
|
$ |
|
|||||||
Operating income (loss): | |||||||||||
HPA | $ |
|
$ |
|
|||||||
CSG |
(
|
|
|||||||||
ACG |
|
|
|||||||||
All other |
(
|
(
|
|||||||||
Operating (loss) income |
(
|
|
|||||||||
Interest expense |
(
|
(
|
|||||||||
Other income (expense), net |
|
(
|
|||||||||
(Loss) income before income taxes | $ |
(
|
$ |
|
Three Months Ended | |||||||||||
July 1, 2023 | July 2, 2022 | ||||||||||
Reconciliation of "All other" category: | |||||||||||
Stock-based compensation expense | $ |
(
|
$ |
(
|
|||||||
Amortization of intangible assets |
(
|
(
|
|||||||||
Restructuring related charges
(1)
|
(
|
(
|
|||||||||
Acquisition and integration related costs
|
(
|
(
|
|||||||||
Charges associated with a long-term capacity reservation agreement |
|
(
|
|||||||||
Other |
(
|
|
|||||||||
Loss from operations for "All other" | $ |
(
|
$ |
(
|
Three Months Ended | |||||||||||
July 1, 2023 | July 2, 2022 | ||||||||||
Numerator: | |||||||||||
Numerator for basic and diluted net (loss) income per share — net (loss) income available to common stockholders | $ |
(
|
$ |
|
|||||||
Denominator: | |||||||||||
Denominator for basic net (loss) income per share — weighted-average shares |
|
|
|||||||||
Effect of dilutive securities: | |||||||||||
Stock-based awards
|
|
|
|||||||||
Denominator for diluted net (loss) income per share — adjusted weighted-average shares and assumed conversions |
|
|
|||||||||
Basic net (loss) income per share | $ |
(
|
$ |
|
|||||||
Diluted net (loss) income per share | $ |
(
|
$ |
|
Three Months Ended | |||||||||||||||||||||||||||||||||||
July 1, 2023 |
% of
Revenue |
July 2, 2022 |
% of
Revenue |
Increase (Decrease) |
Percentage
Change |
||||||||||||||||||||||||||||||
Revenue | $ |
|
100.0 | % | $ |
|
100.0 | % | $ | (384,194) | (37.1) | % | |||||||||||||||||||||||
Cost of goods sold |
|
64.8 |
|
63.8 | (238,014) | (36.1) | |||||||||||||||||||||||||||||
Gross profit | 229,070 | 35.2 | 375,250 | 36.2 | (146,180) | (39.0) | |||||||||||||||||||||||||||||
Research and development |
|
25.1 |
|
16.3 | (5,478) | (3.2) | |||||||||||||||||||||||||||||
Selling, general and administrative |
|
16.2 |
|
9.8 | 3,608 | 3.5 | |||||||||||||||||||||||||||||
Other operating expense |
|
1.3 |
|
0.3 | 5,685 | 189.0 | |||||||||||||||||||||||||||||
Operating (loss) income | $ | (48,136) | (7.4) | % | $ | 101,859 | 9.8 | % | $ | (149,995) | (147.3) | % |
Three Months Ended | ||||||||||||||||||||||||||
(In thousands, except percentages) | July 1, 2023 | July 2, 2022 | Decrease |
Percentage
Change |
||||||||||||||||||||||
Revenue | $ |
|
$ |
|
$ | (71,259) | (33.8) | % | ||||||||||||||||||
Operating income |
|
|
(46,790) | (66.1) | ||||||||||||||||||||||
Operating income as a % of revenue | 17.2 | % | 33.5 | % |
Three Months Ended | ||||||||||||||||||||||||||
(In thousands, except percentages) | July 1, 2023 | July 2, 2022 | Decrease |
Percentage
Change |
||||||||||||||||||||||
Revenue | $ |
|
$ |
|
$ | (53,052) | (34.8) | % | ||||||||||||||||||
Operating (loss) income |
(
|
|
(31,399) | (279.4) | ||||||||||||||||||||||
Operating (loss) income as a % of revenue | (20.3) | % | 7.4 | % |
Three Months Ended | ||||||||||||||||||||||||||
(In thousands, except percentages) | July 1, 2023 | July 2, 2022 | Decrease |
Percentage
Change |
||||||||||||||||||||||
Revenue | $ |
|
$ |
|
$ | (259,883) | (38.7) | % | ||||||||||||||||||
Operating income |
|
|
(157,375) | (77.8) | ||||||||||||||||||||||
Operating income as a % of revenue | 10.9 | % | 30.1 | % |
Three Months Ended | |||||||||||
(In thousands) | July 1, 2023 | July 2, 2022 | |||||||||
Interest expense | $ | (17,261) | $ | (17,252) | |||||||
Other income (expense), net | 13,716 | (5,062) | |||||||||
Income tax benefit (expense) | 8,101 | (10,661) |
Summarized Balance Sheets
(in thousands)
|
July 1, 2023 | April 1, 2023 | |||||||||
ASSETS | |||||||||||
Current assets
(1)
|
$ | 986,646 | $ | 972,989 | |||||||
Non-current assets | 2,345,039 | 2,398,287 | |||||||||
LIABILITIES | |||||||||||
Current liabilities | $ | 216,074 | $ | 296,049 | |||||||
Long-term liabilities
(2)
|
2,740,775 | 2,689,824 |
Summarized Statement of Operations | Three Months Ended | |||||||
(in thousands) | July 1, 2023 | |||||||
Revenue | $ | 252,078 | ||||||
Gross profit | 39,401 | |||||||
Net loss | (62,963) |
Period | Total number of shares purchased (in thousands) | Average price paid per share | Total number of shares purchased as part of publicly announced plans or programs (in thousands) |
Approximate dollar value of shares that may yet be purchased under the plans or programs
(in millions) |
||||||||||||||||||||||
April 2, 2023 to April 29, 2023 | 149 | $ | 94.61 | 149 | $ | 1,690.9 | ||||||||||||||||||||
April 30, 2023 to May 27, 2023 | 164 | 92.85 | 164 | 1,675.7 | ||||||||||||||||||||||
May 28, 2023 to July 1, 2023 | 720 | 98.16 | 720 | 1,605.0 | ||||||||||||||||||||||
Total | 1,033 | $ | 96.81 | 1,033 |
Name and Title | Action | Date | Expiration of Plan |
Number of Shares to be Sold
(1)
|
||||||||||||||||||||||
|
|
|
|
|
||||||||||||||||||||||
|
|
|
|
|
||||||||||||||||||||||
|
|
|
|
|
||||||||||||||||||||||
|
|
|
|
|
||||||||||||||||||||||
|
|
|
|
|
10.1 | |||||
22 | |||||
31.1 | |||||
31.2 | |||||
32.1 | |||||
32.2 | |||||
101 |
The following materials from our Quarterly Report on Form 10-Q for the quarter ended July
1, 2023, f
ormatted in iXBRL (Inline eXtensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets; (ii) the Condensed Consolidated Statements of Operations; (iii) the Condensed Consolidated Statements of Comprehensive (Loss) Income; (iv) the Condensed Consolidated Statements of Stockholders' Equity; (v) the Condensed Consolidated Statements of Cash Flows; and (vi) the Notes to Condensed Consolidated Financial Statements
|
||||
104 |
The cover page from our Quarterly Report on Form 10-Q for the quarter ended
July 1, 2023,
formatted in iXBRL
|
Qorvo, Inc. | |||||||||||
Date: | August 3, 2023 | /s/ Grant A. Brown | |||||||||
Grant A. Brown | |||||||||||
Senior Vice President and Chief Financial Officer
|
|||||||||||
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
---|
DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
---|---|---|---|
Robert C. Frenzel Experience Mr. Frenzel has served as Chairman, President and Chief Executive Officer of Xcel Energy, Inc. (“Xcel Energy”) since December 2021. Mr. Frenzel was previously President and Chief Executive Officer of Xcel Energy, a position he held from August 2021 to January 2022. He also served as President and Chief Operating Officer from March 2020 to August 2021, where he was responsible for Xcel Energy’s four utility operating companies, along with the transmission, distribution and natural gas businesses. From May 2016 to March 2020, Mr. Frenzel served as Executive Vice President and Chief Financial Officer of Xcel Energy. From February 2012 to April 2016, Mr. Frenzel served as Senior Vice President and Chief Financial Officer of Luminant, a subsidiary of Energy Future Holdings Corp. (“EFHC”). From February 2009 to February 2012, he served as Senior Vice President for Corporate Development, Strategy and Mergers and Acquisitions for EFHC. In April 2014, EFHC, the majority of its subsidiaries, including Texas Competitive Energy Holdings (“TCEH”), the parent company of Luminant, filed a voluntary bankruptcy petition under Chapter 11 of the United States Bankruptcy Code. TCEH emerged from Chapter 11 in October 2016. Earlier in his career, Mr. Frenzel advised corporate clients on strategic and financial transactions as a Vice President in the Investment Banking Division at Goldman Sachs, and consulted in the strategy, finance, and economics practice at Arthur Andersen. Mr. Frenzel also served in the United States Navy for six years as a nuclear engineering officer and weapons officer, and was promoted to lieutenant commander in the Navy Reserve following active duty. Qualifications Mr. Frenzel brings public company executive management, supply chain, strategic merger and acquisition, system implementation and risk management experience to our Board. | |||
Philip G.J. McKoy Experience Mr. McKoy has served as Enterprise Lead, Services & Integration at Optum, the health technology and services business of UnitedHealth Group, since February 2023. In his current role, Mr. McKoy is responsible for both Enterprise Shared Services and Enterprise Integration Services. From May 2021 to February 2023, he served as Chief Information Officer of Optum, where he was responsible for accelerating digital adoption among everyone UnitedHealth Group serves. Previously, he served as interim Chief Executive Officer for RallyHealth, Executive Vice President for Digital Transformation at UnitedHealth Group, and Chief Information Officer of UnitedHealthcare. Prior to joining UnitedHealth Group in 2016, Mr. McKoy served as Senior Vice President and Chief Information Officer for Global Loyalty Solutions at Aimia Inc., a data-driven marketing and loyalty analytics company. Before joining Aimia, he served in various roles at Target Corporation, including as Vice President of Target.com where he was responsible for leading the customer-facing digital experience. Earlier in his career, Mr. McKoy advised companies on technology-enabled business strategies as a Senior Manager for Accenture. Other Board Service Mr. McKoy served as a director of TrueCar from October 2018 through December 2021. Qualifications Mr. McKoy brings extensive experience in deploying technology and leading digital transformations at customer-focused companies to our Board. | |||
John D. Buck Experience Mr. Buck serves as our non-executive Chairman of the Board. Mr. Buck is the principal owner of Whitefish Ventures, LLC, a family investment fund. He has been its Chief Executive Officer since 2000. Mr. Buck was Chief Executive Officer of Medica, the second largest health benefits plan in Minnesota, from February 2002 to May 2003. From 1996 to 2000, he worked for Fingerhut Companies, Inc. with his last assignment as President and Chief Operating Officer, and played an integral role in developing the business services area of the company. Prior to Fingerhut, Mr. Buck was Vice President of Administration at Alliant Techsystems, a leading supplier of aerospace and defense technologies. Prior to that, Mr. Buck spent 21 years at Honeywell, Inc., including a four-year international posting, and most recently serving as Vice President of Administration. Other Board Service Mr. Buck is Chairman of the Board of Directors of Medica, served as a director of Evine Live, Inc. from 2004 to 2015, and served as a director of Round River Research from 2017 to 2021. Qualifications Mr. Buck brings financial, strategic and leadership experience, including health benefit plan experience, to our Board. | |||
Donald J. Zurbay Experience Mr. Zurbay became our President and Chief Executive Officer in October 2022. Mr. Zurbay previously served as our Chief Financial Officer from June 2018 through October 2022. Prior to that, Mr. Zurbay served as Vice President and Chief Financial Officer at global medical device manufacturer St. Jude Medical, Inc. from August 2012 through the January 2017 acquisition of St. Jude Medical by Abbott Laboratories. At St. Jude Medical, Mr. Zurbay was responsible for all accounting, financial and business development activities. He joined St. Jude Medical in 2003 and held various leadership positions, including Director of Finance and Vice President and Corporate Controller. Prior to joining St. Jude Medical, Mr. Zurbay worked at PricewaterhouseCoopers for five years as an Assurance and Business Advisory Services Senior Manager. Before joining PricewaterhouseCoopers, he was a General Accounting Manager at The Valspar Corporation. Mr. Zurbay started his career at Deloitte & Touche as an auditor in 1989. Other Board Service Mr. Zurbay served as a director of Avedro, Inc. from its February 2019 initial public offering through its November 2019 sale. He has served as a director of Silk Road Medical, Inc. since March 2018 and as a director of Sight Sciences, Inc. since July 2020. Qualifications Mr. Zurbay brings strategic and leadership experience, including healthcare experience, to our Board. |
|
Name and Principal
Position
|
| |
Fiscal
Year
|
| |
Salary
($)
|
| |
Stock
Awards
($)
|
| |
Option
Awards
($)
|
| |
Non-Equity
Incentive
Plan Compen- sation
($)
|
| |
All Other
Compen-sation
($)
|
| |
Total
($)
|
|
|
Donald J. Zurbay
Chief Executive Officer
|
| |
2024
|
| |
900,001
|
| |
3,063,124
|
| |
1,000,000
|
| |
813,713
|
| |
118,674
|
| |
5,895,511
|
|
|
2023
|
| |
756,831
|
| |
2,420,372
|
| |
1,468,751
|
| |
769,379
|
| |
125,535
|
| |
5,540,867
|
| |||
|
2022
|
| |
570,689
|
| |
1,126,784
|
| |
301,880
|
| |
539,036
|
| |
51,307
|
| |
2,589,695
|
| |||
|
Kevin M. Barry
Chief Financial Officer
|
| |
2024
|
| |
491,908
|
| |
612,604
|
| |
200,004
|
| |
268,200
|
| |
55,894
|
| |
1,628,611
|
|
|
2023
|
| |
386,416
|
| |
529,929
|
| |
70,001
|
| |
255,875
|
| |
51,348
|
| |
1,293,569
|
| |||
|
Kevin M. Pohlman
Chief Operating Officer
|
| |
2024
|
| |
512,404
|
| |
918,958
|
| |
300,001
|
| |
279,375
|
| |
99,705
|
| |
2,110,444
|
|
|
2023
|
| |
461,258
|
| |
847,338
|
| |
162,504
|
| |
293,216
|
| |
91,409
|
| |
1,855,726
|
| |||
|
2022
|
| |
423,546
|
| |
545,662
|
| |
150,944
|
| |
330,944
|
| |
131,826
|
| |
1,582,922
|
| |||
|
Les B. Korsh
Chief Legal Officer and Corporate Secretary
|
| |
2024
|
| |
474,429
|
| |
842,344
|
| |
274,999
|
| |
260,117
|
| |
118,429
|
| |
1,970,318
|
|
|
2023
|
| |
447,933
|
| |
584,757
|
| |
150,001
|
| |
268,137
|
| |
73,636
|
| |
1,524,464
|
| |||
|
2022
|
| |
434,658
|
| |
509,048
|
| |
138,360
|
| |
298,491
|
| |
156,982
|
| |
1,537,539
|
| |||
|
Timothy E. Rogan
Former President, Patterson Dental
|
| |
2024
|
| |
448,279
|
| |
574,332
|
| |
187,498
|
| |
192,938
|
| |
85,205
|
| |
1,488,253
|
|
|
2023
|
| |
428,337
|
| |
413,765
|
| |
137,498
|
| |
218,909
|
| |
49,174
|
| |
1,247,683
|
|
Customers
Customer name | Ticker |
---|---|
Teradyne, Inc. | TER |
No Suppliers Found
Price
Yield
Owner | Position | Direct Shares | Indirect Shares |
---|---|---|---|
Zurbay Donald | - | 222,736 | 1,243 |
POHLMAN KEVIN M | - | 157,297 | 1,923 |
Zurbay Donald | - | 141,923 | 1,176 |
POHLMAN KEVIN M | - | 122,438 | 1,829 |
KORSH LES B | - | 102,713 | 2,255 |
KORSH LES B | - | 78,095 | 2,119 |
BARRY KEVIN MICHAEL | - | 42,821 | 1,622 |
ROGAN TIMOTHY E | - | 40,382 | 16,927 |
BARRY KEVIN MICHAEL | - | 23,103 | 1,592 |
BERGESON SAMANTHA L | - | 20,587 | 985 |
AGARWAL MEENU | - | 12,788 | 0 |
BERGESON SAMANTHA L | - | 11,196 | 926 |